LumiraDx Demonstrates Transformative Tests and Technologies

LumiraDx (London, UK) is presenting its innovative, next-generation point-of-care diagnostics Platform and broad test menu alongside its Fast Lab Solutions at MEDICA 2023.

The LumiraDx Platform is an innovative, next-generation point-of-care system that combines a small, portable instrument, advanced low-cost test strip, and seamless digital connectivity. Its proprietary technology enables it to deliver exceptional point-of-care clinical performance while being simple and easy to use. LumiraDx offers various tests that run on the highly portable LumiraDx Platform, such as the LumiraDx NT-proBNP test which is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is the only fingerstick NT-proBNP test currently commercially available. The rapid microfluidic immunofluorescence assay can aid in the diagnosis of congestive heart failure (CHF).

LumiraDx also offers its highly sensitive C-Reactive Protein (CRP) point-of-care antigen test that runs on the portable LumiraDx platform which weighs just over a kilogram. The point of care CRP test can be used in multiple clinical settings to help reduce unnecessary antibiotic prescribing that leads to antimicrobial resistance. From a tiny sample of finger-prick blood, the CRP test gives results within four minutes. Additionally, LumiraDx’s HbA1c test for professional use across multiple care settings is used alongside the LumiraDx Platform. The test monitors known diabetic patients’ HbA1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes. Providing results in less than seven minutes from sample application, the test allows improved efficiency and convenience with on-the-spot diabetes screening and monitoring at the patient’s side.

At MEDICA 2023, LumiraDx is highlighting its LumiraDx INR Test which is an enzyme kinetic assay based on Thrombin activity. The coagulation cascade is activated by the test reagents and INR is calculated from the measured PT-time. Haematocrit is also measured on the strip to ensure patients are within the 25-55% range. The accuracy of the LumiraDx INR Test is comparable to the ACL Elite lab reference method. Another test that supports confident decisions at the point of care with the LumiraDx Platform is the LumiraDx D-Dimer Test which is a rapid microfluidic immunoassay for quantitative determination of D-Dimer. It is the only D-Dimer Test providing fast, accurate, quantitative results in just 6 minutes from a fingerstick blood sample.

Related Links:
LumiraDx